Answers are grounded in this paper and cite their sources.
Purpose Neoadjuvant chemotherapy (NAC), with or without immunotherapy (IO), is increasingly used in patients with breast cancer and may facilitate breast-conserving surgery (BCS). Because these therapies may alter physiologic reserve and perioperative care needs, we evaluated their associations with anesthetic management and postoperative recovery. Patients and Methods This retrospective cohort study included 374 patients with stage II–III breast cancer undergoing BCS at a high-volume ambulatory cancer center. Patients were categorized as receiving NAC, NAC+IO, or no neoadjuvant therapy. Primary outcomes were use of general anesthesia (GA) and postanesthesia care unit length of stay (PACU LOS). Multivariable models adjusted for age, body mass index, receptor subtype, tumor stage, and nodal status; the PACU LOS model additionally adjusted for surgery start time. Secondary outcomes included intraoperative propofol and opioid dosing per surgical hour and 30-day postoperative adverse events. Results NAC was associated with a 29% higher adjusted probability of GA use (95% CI, 15%–43%) and a 1.4-hour longer PACU LOS (P=.001). Among patients receiving NAC, IO was associated with an 18% lower adjusted probability of GA use (95% CI, 3.1%–33%) and a 0.96-hour shorter PACU LOS (P=.031). Intraoperative opioid requirements and 30-day postoperative adverse events did not differ meaningfully across treatment groups. Differences in propofol dosing were statistically significant but modest. Conclusion Neoadjuvant treatment exposure was associated with differences in anesthetic approach and postoperative recovery despite low complication rates. These findings support treatment-informed perioperative planning and multidisciplinary coordination for patients undergoing BCS. MicroAbstract In this retrospective cohort of 374 patients undergoing breast-conserving surgery, neoadjuvant chemotherapy was associated with greater general anesthesia use and longer postoperative recovery, despite low complication rates. The addition of immunotherapy was associated with lower general anesthesia use and shorter recovery among chemotherapy-treated patients. Neoadjuvant treatment exposure may help inform perioperative planning and recovery-unit resource allocation.
No takes yet. Share an insight, caveat, or question.
Sampathkumar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: